Back to Search
Start Over
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
- Source :
-
British journal of haematology [Br J Haematol] 2023 Dec; Vol. 203 (5), pp. 774-780. Date of Electronic Publication: 2023 Aug 16. - Publication Year :
- 2023
-
Abstract
- Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (nā=ā2 Grade 1, nā=ā5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.<br /> (© 2023 British Society for Haematology and John Wiley & Sons Ltd.)
- Subjects :
- Adult
Humans
Immunotherapy, Adoptive adverse effects
Immunotherapy, Adoptive methods
Receptors, Antigen, T-Cell therapeutic use
T-Lymphocytes
Treatment Outcome
Antigens, CD19
Central Nervous System
Cell- and Tissue-Based Therapy
Lymphoma, Mantle-Cell drug therapy
Receptors, Chimeric Antigen therapeutic use
Neurotoxicity Syndromes drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 203
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 37584155
- Full Text :
- https://doi.org/10.1111/bjh.19037